Minimally Invasive Laser Therapy Shows Promise for Drug-Resistant Epilepsy
• A study published in _Annals of Neurology_ highlights the effectiveness of magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) for drug-resistant epilepsy caused by periventricular nodular heterotopia (PNVH).
• The MRgLITT procedure precisely targets and destroys abnormal brain tissues responsible for seizures, guided by detailed brain mapping using stereo-electroencephalography (SEEG).
• Results showed that up to 80% of patients with localized abnormal brain tissue became seizure-free after the SEEG-guided MRgLITT procedure, offering a life-changing option.
• This minimally invasive approach offers a potential game-changer for individuals struggling with medication-resistant epilepsy, avoiding more invasive brain surgeries.
MDA Awards $500,000 Grant to HEALEY ALS Platform Trial at Mass General
• The Muscular Dystrophy Association (MDA) has awarded a $500,000 grant to Massachusetts General Hospital (MGH) to support the HEALEY ALS Platform Trial.
• The HEALEY ALS Platform Trial aims to accelerate the development of effective treatments for amyotrophic lateral sclerosis (ALS) by testing multiple therapies simultaneously.
• The grant will enhance patient outreach and recruitment, explore new biomarkers, and engage with the FDA to adapt the trial based on previous experience.
• MDA's commitment to ALS research dates back to the 1950s, with over $176 million invested to date, supporting research, care, and advocacy for the ALS community.
© Copyright 2025. All Rights Reserved by MedPath